Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.

Cellular transformation and tumor development result from an accumulation of mutational and epigenetic changes that alter normal cell growth and survival pathways. For the last 100 years, there has been a vigorous debate as to whether the unmanipulated immune system can detect and eliminate such altered host derived cells despite the fact that cancer cells frequently express either abnormal proteins or abnormal levels of normal cellular proteins that function as tumor antigens. In this review, we discuss the current state of this argument and point out some of the recent key experiments demonstrating that immunity not only protects the host from cancer development (i.e., provides a cancer immunosurveillance function) but also can promote tumor growth, sometimes by generating more aggressive tumors. The terminology "cancer immunoediting" has been used to describe this dual host protective and tumor promoting action of immunity, and herein we summarize the ever-increasing experimental and clinical data that support the validity of this concept.

[1]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[2]  L. Lanier,et al.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[4]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[5]  Mariano J. Alvarez,et al.  Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. , 2004, Cancer cell.

[6]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[7]  Julia M. Lewis,et al.  The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin Cancer , 2003, The Journal of experimental medicine.

[8]  M. Smyth,et al.  Perforin is a major contributor to NK cell control of tumor metastasis. , 1999, Journal of immunology.

[9]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[10]  E. Coccia,et al.  Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. , 1987, Haematologica.

[11]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[12]  F. Belardelli,et al.  Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice , 1988, The Journal of experimental medicine.

[13]  T. Spies,et al.  MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function , 2001 .

[14]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[15]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[16]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[17]  S. Sakaguchi Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[18]  I. Penn Malignant melanoma in organ allograft recipients. , 1996, Transplantation.

[19]  C. Boshoff,et al.  Aids-related malignancies , 2002, Nature Reviews Cancer.

[20]  S. Lowe,et al.  Control of apoptosis by p53 , 2003, Oncogene.

[21]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[22]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[23]  I. Svane,et al.  Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[24]  L. Old,et al.  Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Dhodapkar,et al.  A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma , 2003, The Journal of experimental medicine.

[26]  M. Horton,et al.  Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. , 1997, Journal of immunology.

[27]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[28]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[29]  R. Flavell,et al.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells , 2001, Nature Medicine.

[30]  M BURNET,et al.  Cancer—A Biological Approach* , 1957, British medical journal.

[31]  J. Rygaard,et al.  The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. , 2009, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.

[32]  M. Smyth Type I interferon and cancer immunoediting , 2005, Nature Immunology.

[33]  P. Srivastava,et al.  Roles of heat-shock proteins in antigen presentation and cross-presentation. , 2002, Current opinion in immunology.

[34]  Hideo Negishi,et al.  Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.

[35]  J. Platt,et al.  Receptor-Mediated Monitoring of Tissue Well-Being Via Detection of Soluble Heparan Sulfate by Toll-Like Receptor 41 , 2002, The Journal of Immunology.

[36]  S. Sakaguchi Regulatory T cells , 2000, Cell.

[37]  A. Diefenbach,et al.  A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity , 2003, European journal of immunology.

[38]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.

[39]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[40]  D. Carbone,et al.  Tumor-host immune interactions and dendritic cell dysfunction. , 2004, Advances in cancer research.

[41]  A. Marx,et al.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. , 2001, Blood.

[42]  M. Smyth,et al.  NKT cells - conductors of tumor immunity? , 2002, Current opinion in immunology.

[43]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[44]  T. Ahrens,et al.  Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4 , 2002, The Journal of experimental medicine.

[45]  Zihai Li,et al.  Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. , 2003, Cancer immunity.

[46]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[47]  J. Hess,et al.  Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. , 2004, Blood.

[48]  M. Smyth,et al.  A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas , 2002, The Journal of experimental medicine.

[49]  T. Tüting,et al.  Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.

[50]  E. Nakayama,et al.  Sequential Involvement of Two Distinct CD4+ Regulatory T Cells during the Course of Transplantable Tumor Growth and Protection from 3–Methylcholanthrene‐induced Tumorigenesis by CD25–depletion , 2002, Japanese journal of cancer research : Gann.

[51]  L. Loeb,et al.  Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.

[52]  D. Longo,et al.  Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. , 1992, Journal of immunology.

[53]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[54]  N. Shastri,et al.  Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages , 2000, Nature Immunology.

[55]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[56]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[57]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[58]  Hiroshi Sato,et al.  Requirement for Vα14 NKT Cells in IL-12-Mediated Rejection of Tumors , 1997 .

[59]  P. Szlosarek,et al.  Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .

[60]  M. V. D. van den Brink,et al.  Nature's TRAIL--on a path to cancer immunotherapy. , 2003, Immunity.

[61]  N. Malats,et al.  Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Leder,et al.  IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.

[63]  L. Old,et al.  Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes , 2004, Immunogenetics.

[64]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[65]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[66]  S. Ferrone,et al.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. , 2002, Cancer research.

[67]  R. Darnell Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Darnell,et al.  Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. , 2001, Annual review of neuroscience.

[69]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[70]  P. Medawar The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council. , 1944, Journal of anatomy.

[71]  Old Lj,et al.  Immunology of Experimental Tumors , 1964 .

[72]  E. Unanue,et al.  Natural Immunity: A T‐Cell‐Independent Pathway of Macrophage Activation, Defined in the scid Mouse , 1991, Immunological reviews.

[73]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[74]  C. Sutherland,et al.  ULBP4 is a novel ligand for human NKG2D. , 2003, Biochemical and biophysical research communications.

[75]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[76]  Michael J. Wilson,et al.  A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. , 2002, Genomics.

[77]  M. Smyth,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.

[78]  F. Burnet The concept of immunological surveillance. , 1970, Progress in experimental tumor research.

[79]  N. Fausto,et al.  Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice , 2000, The Journal of experimental medicine.

[80]  R. Flavell,et al.  Transforming growth factor-β in T-cell biology , 2002, Nature Reviews Immunology.

[81]  R. Darnell,et al.  Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies , 1993, The Lancet.

[82]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[83]  L. Sherman,et al.  The composition of the T cell receptor repertoire in nude mice. , 1987, Journal of immunology.

[84]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[85]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[86]  M. Smyth,et al.  Alpha-galactosylceramide: potential immunomodulatory activity and future application. , 2004, Current medicinal chemistry.

[87]  G. Forni,et al.  α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[88]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[89]  L. Thomas THE YALE JOURNAL OF BIOLOGY AND MEDICINE 55 (1982), 329-333 On Immunosurveillance in Human Cancer , 1982 .

[90]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[91]  D. Carbone,et al.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[93]  Julia M. Lewis,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[94]  J. Daly,et al.  Long-term spontaneous tumor incidence in neonatally thymectomized mice. , 1973, Journal of immunology.

[95]  K. Weinhold,et al.  The tumor dormant state. , 1981, Advances in cancer research.

[96]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[97]  M. Smyth,et al.  NKT cells: facts, functions and fallacies. , 2000, Immunology today.

[98]  O. Tsitsilonis,et al.  Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice , 2000, European journal of immunology.

[99]  Lin Zhang,et al.  Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A , 2004, Nature Medicine.

[100]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[101]  E. Lenkiewicz,et al.  Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils , 2004, Science.

[102]  G. Trinchieri,et al.  Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.

[103]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[104]  Piero Musiani,et al.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. , 2003, The Journal of clinical investigation.

[105]  R. Flavell,et al.  Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis , 1997, Molecular and cellular biology.

[106]  Wancai Yang,et al.  γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity , 2003, The Journal of experimental medicine.

[107]  Peter Greenwald,et al.  The antioxidant conundrum in cancer. , 2003, Cancer research.

[108]  S. Bahram,et al.  Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[109]  H. Kaplan Role of Immunologic Disturbance in Human Oncogenesis: Some Facts and Fancies , 1971, British Journal of Cancer.

[110]  D. Margulies,et al.  MHC class I recognition by Ly49 natural killer cell receptors. , 2002, Molecular immunology.

[111]  M. Marino,et al.  Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. , 1999, Cancer research.

[112]  T. Sayers,et al.  NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer , 2004, The Journal of experimental medicine.

[113]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[114]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[115]  Y. Shinkai,et al.  Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo , 1990, The Journal of experimental medicine.

[116]  Yi Luo,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand , 2004, Cancer Research.

[117]  K. Macleod Tumor suppressor genes. , 2000, Current opinion in genetics & development.

[118]  R. MacKie,et al.  Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. , 2003, The New England journal of medicine.

[119]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[120]  S. Riddell,et al.  Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells , 2001, Nature Immunology.

[121]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[122]  M. Bevan,et al.  Specificity of cytotoxic T cells from athymic mice , 1980, The Journal of experimental medicine.

[123]  A. Hayday,et al.  A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice , 1996, The Journal of experimental medicine.

[124]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[125]  N. Hayashi,et al.  Critical Role of MHC Class I-Related Chain A and B Expression on IFN-α-Stimulated Dendritic Cells in NK Cell Activation: Impairment in Chronic Hepatitis C Virus Infection 1 , 2003, The Journal of Immunology.

[126]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[127]  T. Giese,et al.  Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions , 1998, The Journal of experimental medicine.

[128]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[129]  R. Schreiber,et al.  IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. , 2005, Cancer research.

[130]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[131]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[132]  T. Noda,et al.  Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. , 2004, The Journal of clinical investigation.

[133]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[134]  F. Garrido,et al.  The HLA crossroad in tumor immunology. , 2000, Human immunology.

[135]  M. Smyth,et al.  An Essential Role for Tumor Necrosis Factor in Natural Killer Cell–mediated Tumor Rejection in the Peritoneum , 1998, The Journal of experimental medicine.

[136]  S. Bauer,et al.  Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. , 1998, Science.

[137]  N. Ponzio,et al.  B cell lymphomas of C57L/J mice; the role of natural killer cells and T helper cells in lymphoma development and growth. , 2000, Leukemia research.

[138]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[139]  M. Smyth,et al.  Cutting Edge: Novel Priming of Tumor-Specific Immunity by NKG2D-Triggered NK Cell-Mediated Tumor Rejection and Th1-Independent CD4+ T Cell Pathway1 , 2004, The Journal of Immunology.

[140]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[141]  N. Burstein,et al.  Neonatal Thymectomy and Non-viral Mammary Tumours in Mice , 1971, Nature.

[142]  B. Ruebner,et al.  Anti-mu induces lymphoma in germfree congenitally athymic (nude) but not in heterozygous (nu/+) mice. , 1983, Journal of immunology.

[143]  P. Foster,et al.  Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.

[144]  R. Zinkernagel,et al.  Perforin dependence of natural killer cell‐mediated tumor control in vivo , 1995, European journal of immunology.

[145]  G. Klein Immunological surveillance against neoplasia. , 1973, Harvey lectures.

[146]  P. Hersey,et al.  Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3γ* , 1997, The Journal of Biological Chemistry.

[147]  J. Blay,et al.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. , 2004, The Journal of clinical investigation.

[148]  M. Smyth,et al.  Cutting Edge: Tumor Rejection Mediated by NKG2D Receptor-Ligand Interaction Is Dependent upon Perforin1 , 2002, The Journal of Immunology.

[149]  F. Alt,et al.  Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer , 2003, The Journal of experimental medicine.

[150]  H. Richardson,et al.  Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[151]  J. Roder,et al.  Spontaneous and induced primary oncogenesis in natural killer (nk)‐cell‐deficient beige mutant mice , 1985, International journal of cancer.

[152]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[153]  S. Johnson Effect of thymectomy on the induction of skin tumours by dibenzanthracene, and of breast tumours by dimethylbenzanthracene, in mice of the IF strain. , 1968, British Journal of Cancer.

[154]  S. Akira,et al.  Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice , 2004, Cancer Research.

[155]  K. Loeb,et al.  Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[156]  T. Spies,et al.  Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB , 1999 .

[157]  A. Toubert,et al.  Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[158]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[159]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[160]  M. Colonna,et al.  A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. , 2004, Blood.

[161]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[162]  R. Armitage,et al.  ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. , 2001, Immunity.

[163]  M. Pfreundschuh,et al.  Cell surface antigens of human renal cancer defined by autologous typing , 1979, The Journal of experimental medicine.

[164]  L. Old Cancer vaccines 2003: opening address. , 2003, Cancer immunity.

[165]  S. Ikehara,et al.  Functional T cells in athymic nude mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[166]  F. Belardelli,et al.  Endogenous type I interferons as a defense against tumors. , 2002, Cytokine & growth factor reviews.

[167]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[168]  L. Old,et al.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[169]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[170]  P. Hogan,et al.  Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. , 1998, Transplantation.

[171]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[172]  D. Katz,et al.  Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. , 1983, Journal of immunology.

[173]  W. Coley The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[174]  R. Darnell,et al.  Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration , 2000, Annals of neurology.

[175]  J. Kirkwood,et al.  Interferon-alpha in tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[176]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[177]  J. Becker,et al.  Expression of stress-induced MHC class I related chain molecules on human melanoma. , 2002, The Journal of investigative dermatology.

[178]  D. Fremont,et al.  Cutting Edge: Murine UL16-Binding Protein-Like Transcript 1: A Newly Described Transcript Encoding a High-Affinity Ligand for Murine NKG2D1 , 2002, The Journal of Immunology.

[179]  T. Starzl,et al.  Malignant lymphomas in transplantation patients: a review of the world experience. , 1970, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology.

[180]  H. Rammensee,et al.  Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.

[181]  S. Rosenberg,et al.  Human tumor antigens for cancer vaccine development , 1999, Immunological reviews.

[182]  J. Trapani,et al.  Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection , 2003, The Journal of Immunology.

[183]  H. Ljunggren,et al.  Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice , 1996, European journal of immunology.

[184]  J. Rygaard,et al.  Is immunological surveillance not a cell-mediated immune function? , 1974, Transplantation.

[185]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[186]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[187]  L. Lanier,et al.  Ligands for natural killer cell receptors: redundancy or specificity , 2001, Immunological reviews.

[188]  L. Old Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. , 1981, Cancer research.

[189]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[190]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[191]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[192]  M. Colonna,et al.  NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation , 2002, Nature Immunology.

[193]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[194]  A. Hayday,et al.  Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance , 2005, Nature Immunology.

[195]  O. Stutman Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.

[196]  A. Winoto,et al.  Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice , 2005, Cell Death and Differentiation.

[197]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[198]  R. Zinkernagel,et al.  Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.

[199]  C. Mackay,et al.  The role of chemokine receptors in primary, effector, and memory immune responses. , 2000, Annual review of immunology.

[200]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[201]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[202]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[203]  L. O'Hanlon Natural born killers: NK cells drafted into the cancer fight. , 2004, Journal of the National Cancer Institute.

[204]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[205]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[206]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[207]  Jeffrey M. Vinocur,et al.  LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells , 2003, Cancer biology & therapy.

[208]  Mark J. Smyth,et al.  Functional significance of the perforin/granzyme cell death pathway , 2002, Nature Reviews Immunology.

[209]  A. Balmain,et al.  Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma , 2004 .

[210]  K. Nomoto,et al.  Immunologic properties of methylcholanthrene-induced sarcomas of neonatally thymectomized mice. , 1969, Journal of the National Cancer Institute.

[211]  C. D. Krause,et al.  Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.

[212]  P. Schlag,et al.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.

[213]  P K Lala,et al.  Role of nitric oxide in carcinogenesis and tumour progression. , 2001, The Lancet. Oncology.

[214]  M. Smyth NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[215]  C. Caux,et al.  Chemokines in cancer. , 2002, Cytokine & growth factor reviews.

[216]  Matthew L. Albert,et al.  Paraneoplastic neurological degenerations: keys to tumour immunity , 2004, Nature Reviews Cancer.

[217]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[218]  O. Stutman Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. , 1979, Journal of the National Cancer Institute.

[219]  P. Musiani,et al.  The intriguing role of polymorphonuclear neutrophils in antitumor reactions. , 2001, Blood.

[220]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[221]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[222]  S. Sakaguchi Immunologic Tolerance Maintained by Regulatory T Cells: Implications for Autoimmunity, Tumor Immunity and Transplantation Tolerance , 2002, Vox sanguinis.

[223]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[224]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[225]  O. Stutman Immunodepression and malignancy. , 1975, Advances in cancer research.

[226]  J. Berzofsky,et al.  Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.

[227]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[228]  A. Chong,et al.  IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. , 1998, Cancer research.

[229]  P. Hersey,et al.  Remission of transplanted melanoma--clinical course and tumour cell characterisation. , 1997, Clinical transplantation.

[230]  M. Burnet IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. , 1964, British medical bulletin.

[231]  M. Nomura,et al.  Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: one of the early inducible clones encodes a novel protein sharing several highly homologous regions with a Drosophila polyhomeotic protein. , 1994, Differentiation; research in biological diversity.

[232]  Y. Shinkai,et al.  Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells , 1990, The Journal of experimental medicine.

[233]  R. Darnell,et al.  Observing the invisible: successful tumor immunity in humans , 2003, Nature Immunology.

[234]  M. Smyth,et al.  Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1 , 2005, The Journal of Immunology.

[235]  D. Raulet Roles of the NKG2D immunoreceptor and its ligands , 2003, Nature Reviews Immunology.

[236]  A. M. Hicks,et al.  Spontaneous regression of advanced cancer: Identification of a unique genetically determined, age-dependent trait in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[237]  D. Pellicci,et al.  The Elusive NKT Cell Antigen--Is the Search Over? , 2004, Science.

[238]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[239]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[240]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.

[241]  J. Crawford,et al.  T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.

[242]  Aseem Kumar,et al.  Defective TNF-α-Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases , 1997 .

[243]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[244]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[245]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[246]  H. Mellstedt,et al.  Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A , 2003, International journal of cancer.

[247]  H. Ikeda,et al.  CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[248]  J. Miller,et al.  Effect of Neonatal Thymectomy on the Induction of Sarcomata in C57BL Mice , 1965, Nature.

[249]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[250]  T. Ganz,et al.  An antimicrobial activity of cytolytic T cells mediated by granulysin. , 1998, Science.

[251]  N. Hayashi,et al.  Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid , 2003, International journal of cancer.

[252]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[253]  F. Burnet Immunological Surveillance in Neoplasia , 1971, Transplantation reviews.

[254]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[255]  R. Schreiber,et al.  Response to 'A cancer immunosurveillance controversy' , 2004, Nature Immunology.

[256]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[257]  P. Srivastava,et al.  Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. , 2002, Annual review of immunology.

[258]  S. Coca,et al.  Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.

[259]  C. Janeway Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.

[260]  M. Smyth,et al.  NKT cells and tumor immunity—a double-edged sword , 2000, Nature Immunology.

[261]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[262]  R. Proia,et al.  Lysosomal Glycosphingolipid Recognition by NKT Cells , 2004, Science.

[263]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[264]  M. Smyth,et al.  NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.

[265]  D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[266]  G. Wong,et al.  Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor , 1989, Cell.

[267]  E. Proietti,et al.  Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors , 1983, The Journal of experimental medicine.

[268]  R. Custer,et al.  Spontaneous and induced tumor incidence in germfree "nude" mice. , 1975, Journal of the Reticuloendothelial Society.

[269]  Takuma Hayashi,et al.  Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. , 2002, Cancer research.

[270]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.